Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

BioCardia, Inc.

NASDAQ: BCDA · Life Sciences · 9 alerts · CIK 925741

Share price
$0.7901Close, Nov 16
Market cap
$12M
Shares outstanding
15.14MLatest SEC cover page
Sector
Life Sciences
Industry
Biological Products, (No Diagnostic Substances)SIC 2836

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All BioCardia, Inc. filings on SEC EDGAR ↗

8:31 AM ET 8-K
Business Update

BioCardia Business Update

BioCardia has completed the clinical consultation process with Japan's PMDA regarding application materials for its CardiAMP Cell Therapy System. This milestone allows the company to advance toward a formal marketing approval application for the treatment of ischemic heart failure in Japan, with initial patient treatments and commercial revenues targeted for 2028.

Counterparty
Pharmaceuticals and Medical Devices Agency (PMDA)
9:15 AM ET 8-K
Business Update

BioCardia Business Update

BioCardia announced that the FDA has accepted its revised De Novo pre-submission package for the marketing clearance of its Helix transendocardial delivery catheter. The company expects a substantive review and a meeting with the FDA to discuss the approval pathway during the current quarter.

9:15 AM ET 8-K
Business Update

BioCardia Business Update

BioCardia has submitted a revised Pre-Submission to the FDA Center for Devices and Radiological Health (CDRH) for the approval of its Helix Catheter for therapeutic and diagnostic delivery to the heart. The submission incorporates prior FDA feedback regarding marketing clearance pathways and safety data, with the FDA expected to provide written feedback or hold a meeting within 70 days. An independent clearance would allow BioCardia to partner with other developers of cell, gene, and protein therapeutics requiring targeted cardiac delivery.

Counterparty
FDA
9:15 AM ET 8-K
Business Update

BioCardia Business Update

BioCardia provided a regulatory and clinical update, confirming plans to submit a Shonin pre-market application to Japan's PMDA in Q4 2026 for its CardiAMP cell therapy. The company also intends to file a De Novo pre-submission with the FDA this quarter for its Helix Transendocardial Delivery Catheter System, which could expand its partnership opportunities for cardiac therapeutics.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.